PNS Member-Featured CLinical Trials
PNS Member-Featured Clinical Trials
The following trials have been conducted by members of the PNS. They have not been endorsed by the PNS. Please see information below regarding IRB approval and whether the study has been registered with clincialtrials.gov. Should you have questions or wish to list your study on this page, please contact education@pnsociety.com.
Clinical Trial Search
Please visit clinicaltrials.gov to view all studies. You may search by condition or disease, other terms, and country. Studies may be viewed in list format, by topic, or on the map by region.
Clinical Trial Search
You may search by condition or disease, other terms, and country. Studies may be viewed in list format, by topic, or on the map by region.
Submit a Clinical Trial
Members of the PNS may submit clinical trials for inclusion on this page. If you would like to make a submission, please complete the form at the link below.
PNS Member-Featured Clinical Trials Listing
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP (emnergize)
Primary Investigator: Nicholas Sameul Streicher, MD, MedStar Georgetown University, Washington DC, USA
Contact Info: Anu Bhooshan: anu.r.bhooshan@medstar.net
IRB Approval: Yes
Click Here to view full trial listing
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP (emvigorate)
Primary Investigator: Amro M. Stino, MD, University of Michigan, Ann Arbor, MI, USA
Contact Info: Amro M. Stino: amstino@med.umich.edu
IRB Approval: Yes
Click Here to view full trial listing
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).
Small fiber neuropathy associated with SARS-CoV-2 infection: a laser evoked potentials study
Primary Investigator: Agustina Maria Lascano, MD-PhD, Privat Dozent, University Hospitals of Geneva, Geneva, Switzerland
Co-Investigator: Nehme Mayssam, MD, University Hospitals of Geneva, Geneva, Switzerland
IRB Approval: No
Click Here to view full trial listing
The aim of the study is to confirm (or refute) the presence of SNF in a cohort of patients presenting with complaints compatible with neuropathic pain (e.g., paresthesia, dysesthesia, allodynia) after SARS-CoV-2 infection. Patients will undergo functional and anatomical evaluation (i.e., skin biopsy). In terms of functional assessment of small nerve fiber, patients will be testes with laser evoked potentials (LEPs), quantitative sensory testing (QST) and Electrichemical skin conduction study.
A novel neuromodulation approach to target small fiber neuropathy early in diabetes and measure functional recovery
Primary Investigator: Brian Dalm, MD, The Ohio State University, Columbus, OH, USA
Co-Investigator: Kristy Townsend, PhD, The Ohio State University, Columbus, OH, USA
Contact Info: Alexander Price
IRB Approval: Yes
Click Here to view full trial listing
This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.